NovellusDx Cancer Early Detection Blood Test- Clinical Trial

NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature detection. The investigators' current clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test- discriminating between cancer patients and healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rambam MC

Haifa, 31096, Israel

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

subjects ages 18 and above ICF obtain

Exclusion criteria

none

Treatment and study plan

Primary outcomes

Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test

Time frame: 3.5 years

NovellusDX Cancer Early Detection test will identify participants with significant cancer fingerprint based on tumor protein secretion to the blood circulation in sick subjects.

Sponsors and collaborators

Lead sponsor

Fore Biotherapeutics

Industry

Registry information

Official study title

Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol

Important dates

Study start: 2013
Primary completion: 2016
First posted: Jun 21, 2013
Registry last updated: Mar 29, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed